BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response
Yael Peled, Eilon Ram, Jacob Lavee, Leonid Sternik, Amit Segev, Anat Wieder-Finesod, Michal Mandelboim, Victoria Indenbaum, Itzchak Levy, Ehud Raanani, Yaniv Lustig, Galia Rahav, Yael Peled, Eilon Ram, Jacob Lavee, Leonid Sternik, Amit Segev, Anat Wieder-Finesod, Michal Mandelboim, Victoria Indenbaum, Itzchak Levy, Ehud Raanani, Yaniv Lustig, Galia Rahav
Abstract
Background: Data on the safety and efficacy of SARS-CoV-2 vaccines in immunocompromised populations are sparse.
Methods: We conducted a prospective study of 77 heart transplant (HT) recipients vaccinated with two doses of BNT162b2 vaccine and monitored for adverse events following both doses, the receptor-binding domain (RBD) IgG response, and neutralizing antibodies.
Results: BNT162b2 vaccination was associated with a low rate of adverse events, characterized mostly by pain at the injection site. By a mean 41 days post second dose there were no clinical episodes of rejection, as suggested by a troponin leak or allograft dysfunction. At a mean 21 days following the second dose, IgG anti-RBD antibodies were detectable in 14 (18%) HT recipients. Immune sera neutralized SARS-CoV-2 pseudo-virus in 8 (57%) of those with IgG anti-RBD antibodies. Immunosuppressive regimen containing mycophenolic acid was associated with lower odds of an antibody response (OR = 0.12, p = 0.042).
Conclusions: Whether a longer time-frame for observation of an antibody response is required after vaccination in immunosuppressed individuals remains unknown.
Keywords: BNT162b2 vaccine; antibody response; heart transplantation.
Copyright © 2021 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
References
- Polack FP, Thomas SJ, Kitchin N. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615.
- Voysey M, Clemens SAC, Madhi SA. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.
- Boyarsky BJ, Werbel WA, Avery RK. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA. 2021;325:1784–1786.
- Boyarsky BJ, Ou MT, Greenberg RS. Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients. Transplantation. 2021;105:e56–e57.
- International Society for Heart and Lung Transplantation Guidance from the International Society of Heart and Lung Transplantation regarding the SARS CoV-2 pandemic. Available at:
- Dieterle ME, Haslwanter D, Bortz RH., 3rd A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition. Cell Host Microbe. 2020;28:486–496. e6.
- Wang Z, Schmidt F, Weisblum Y. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616–622.
- Hellerstein M. What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2? Vaccine X. 2020;6
- Natori Y, Shiotsuka M, Slomovic J. A double-blind, randomized trial of high-dose vs standard-dose influenza vaccine in adult solid-organ transplant recipients. Clin Infect Dis. 2018;66:1698–1704.
- Rentenaar RJ, van Diepen FN, Meijer RT. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo. Kidney Int. 2002;62:319–328.
Source: PubMed